Hope for Patients with Mild Idiopathic Pulmonary Fibrosis
Links shared publicly online about this topic.
- 1,159total visits
Hope for Patients with Mild Idiopathic Pulmonary Fibrosis
View full resource at newswise.com
Tags: Lung, Pulmonary Fibrosis, Pulmonology
Most Recently Shared on May 18, 2010 at 2:53 pm By:
Hope for Patients with Mild Idiopathic Pulmonary Fibrosis: A new therapy shows promise for patients with mild idio... http://bit.ly/biNrIt
InterMune Initiates Phase 3 ASCEND Study Of Pirfenidone In IPF - QualityPoint Technologies
qualitypointtech.net — “InterMune (NASDAQ: ITMN) announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF). ASCEND is a multinational, randomized, double-blind, placebo controlled Phase 3 trial designed to evaluate the safety and efficacy of Esbriet® (pirfenidone) in IPF patients with mild to moderate impairment in lung function. The primary endpoint is lung function, as measured by change in forced vital capacity (FVC) fro” View full resource at qualitypointtech.net
Most Recently Shared on July 9, 2011 at 11:00 am By:
InterMune Initiates Phase 3 ASCEND Study Of Pirfenidone In IPF: InterMune (NASDAQ: ITMN) announced that patient en... http://bit.ly/mS6WOK
The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis
news-medical.net — “InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).” View full resource at news-medical.net
Most Recently Shared on May 16, 2011 at 4:38 am By:
The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis: InterMune, Inc. tod... http://bit.ly/kKfLww
Hope for patients with mild idiopathic pulmonary fibrosis
sciencedaily.com — “A new therapy shows promise for patients with mild idiopathic pulmonary fibrosis. According to researchers, inhaled N-acetylcysteine (NAC) monotherapy preserves more lung function in some idiopathic pulmonary fibrosis (IPF) patients than no therapy.” View full resource at sciencedaily.com
Most Recently Shared on May 18, 2010 at 2:45 pm By:
Hope for patients with mild idiopathic pulmonary fibrosis: A new therapy shows promise for patients with mild idio... http://bit.ly/cfKViD
Advertisement
